YPO

Yposkesi is a leading European Contract Development and Manufacturing Organization (CDMO) specializing in viral vector manufacturing for gene and cell therapies. Based in France, the company provides a full range of services from early-stage process development to large-scale commercial manufacturing of Lentiviral and Adeno-Associated Virus (AAV) vectors. Yposkesi was founded in 2016 by AFM-Téléthon and Bpifrance and was subsequently acquired by SK pharmteco in 2021. The company operates state-of-the-art cGMP facilities designed to meet global regulatory standards for Advanced Therapy Medicinal Products (ATMPs). By leveraging proprietary platforms like LentiSure and AAV-SURE, Yposkesi helps biopharmaceutical partners accelerate the transition of innovative therapies from the lab to the patient.